Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Prostate Cancer treatment details. Biologic therapy. Chemotherapy. National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States

Survival: 28.9 months
Toxicity Grade: 3
Treatments: Biologic therapy
Drugs: Taxotere
Country: United States
City/State/Province: Bethesda, Maryland
Hospital: National Cancer Institute, National Institutes of Health
Journal: Link
Date: 7/2004

Patients: This Phase II trial involved a total of 75 patients with hormone refractory (androgen-independent) prostate cancer. Patients were divided into two groups: Group 1 comprised of 25 patients and Group 2 comprised of 50 patients. The median age for patients in Group 2 was 71 years and the median baseline PSA was 59.9 (range 2 1,777).

Treatment: For patients in Group 2, the treatment consisted of the chemotherapy drug, docetaxel (taxotere) plus the anti-angiogenesis drug, thalidomide (thalomid).

Toxicity: For patients in Group 2, grade 3 toxicities included fatigue, allergic reaction, depression, thrombosis, hyperglycemia, thrombocytopenia, neutropenia, and anemia.

Results: For patients in Group 2 the median survival was 28.9 months.

Correspondence: William D. Figg, MD

E-mail to a Friend Email Physician More Information